Clin2
NCT06269120Likely a fitCompleted

Oral semaglutide study for type 2 diabetes in Hungary

Type 2 Diabetes

Treatments studied

Part of Hormones & metabolism clinical trials.

This study looks at how oral semaglutide (a once-daily pill for type 2 diabetes) affects blood sugar, weight, and heart health. It is for people in Hungary who are already starting this medication with their doctor.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
243 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older.
  • You have been diagnosed with type 2 diabetes.
  • You are currently taking metformin, with or without other diabetes pills (like DPP-4 inhibitors or SGLT2 inhibitors) or insulin.
  • Your most recent HbA1c (average blood sugar over 3 months) is above 7.0% (within 90 days before starting the study).
  • You have not taken a GLP-1 receptor agonist (like liraglutide or dulaglutide) in the last 90 days.
  • You are not pregnant, breastfeeding, or planning to become pregnant during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07424430Not yet recruiting
Long-term study of semaglutide effects on heart, kidney, and metabolic health

This study looks at how semaglutide (a medication for type 2 diabetes or weight management) affects your heart, kidneys, and overall metabolic health over time. It uses medical records from LMC endocrinology clinics to track real-world outcomes.

NCT07621419Recruiting
Semaglutide for Type 2 Diabetes in Real-World Care

This study tests how well a diabetes medication called semaglutide works when prescribed in everyday clinical practice in Argentina. Semaglutide comes in two forms—a pill or an injection—and the study tracks how much it lowers blood sugar over one year.

Buenos Aires, Buenos Aires
NCT07046273Not yet recruiting· Phase 3
Semaglutide for type 2 diabetes: a phase 3 trial

This trial tests if a new form of semaglutide works as well as the approved drug Ozempic for lowering blood sugar. It's for adults with type 2 diabetes who are already taking metformin and need better sugar control.

NCT05340868Recruiting
Study body response to oral semaglutide in overweight adults

This study looks at how genetics may affect your body’s early response to oral semaglutide, a weight-related diabetes medicine. You may be considered if you are overweight (or overweight with prediabetes) and can safely take part in the research.

Bialystok, Podlaskie Voivodeship
NCT06909006Not yet recruiting· Phase 3
Semaglutide for type 1 diabetes with higher body weight

This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.

Hillerød, Denmark
NCT07272343Recruiting· Phase 4
Semaglutide vs. diet changes for new type 2 diabetes

This study compares a weekly injection called semaglutide with a calorie-restricted diet to see which helps control blood sugar better. If you have just been diagnosed with type 2 diabetes and have overweight, this trial might help you choose a treatment path.

Jiangxi, Nanchang

Hear when a new Type 2 diabetes trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.